Off-label use of fumarate therapy for granulomatous and inflammatory skin diseases other than psoriasis vulgaris: A retrospective study

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 11, 2012, Pages 1400-1406

  Klein, A ^a   Coras, B ^b   Landthaler, M ^a   Babilas, P ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b Klinikum Schwabing   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FUMADERM; FUMARIC ACID; HYDROXYCHLOROQUINE; METHOTREXATE;

ABDOMINAL DISTENSION; ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; DERMATITIS; DIARRHEA; DISCOID LUPUS ERYTHEMATOSUS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EOSINOPHILIA; FATIGUE; FEMALE; FLUSHING; GRANULOMA ANNULARE; GRANULOMATOUS SKIN DISEASE; HUMAN; HYPERTRANSAMINASEMIA; LICHEN PLANUS; LYMPHOCYTOPENIA; MALE; NAUSEA; OFF LABEL DRUG USE; PITYRIASIS RUBRA PILARIS; PRIORITY JOURNAL; PSORIASIS VULGARIS; SARCOIDOSIS; SIDE EFFECT; STOMACH DISEASE;

ADOLESCENT; ADULT; AGED; DERMATITIS; FEMALE; FUMARATES; GRANULOMA; HUMANS; MALE; MIDDLE AGED; OFF-LABEL USE; PSORIASIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84867572315     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04303.x     Document Type: Article

References (35)

1. Breuer K, Gutzmer R, Volker B, Kapp A, Werfel T,. Therapy of noninfectious granulomatous skin diseases with fumaric acid esters. Br J Dermatol 2005; 152: 1290-1295. (Pubitemid 40933431)
2. Kreuter A, Knierim C, Stucker M, et al. Fumaric acid esters in necrobiosis lipoidica: results of a prospective noncontrolled study. Br J Dermatol 2005; 153: 802-807. (Pubitemid 41415909)
3. Nowack U, Gambichler T, Hanefeld C, Kastner U, Altmeyer P,. Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters. BMC Dermatol 2002; 2: 15.
4. Guenova E, Hoetzenecker W,. Treatment of recurrent aphthous stomatitis with fumaric acid esters. Arch Dermatol 2011; 147: 282-284.
5. Venten I, Hess N, Hirschmuller A, Altmeyer P, Brockmeyer N,. Treatment of therapy-resistant Alopecia areata with fumaric acid esters. Eur J Med Res 2006; 11: 300-305.
6. Litjens NH, van Strijen E, van Gulpen C, et al. In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC Pharmacol 2004; 4: 22.
7. Werdenberg D, Joshi R, Wolffram S, Merkle HP, Langguth P,. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos 2003; 24: 259-273. (Pubitemid 37160613)
8. Rostami-Yazdi M, Clement B, Schmidt TJ, Schinor D, Mrowietz U,. Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. J Invest Dermatol 2009; 129: 231-234.
9. Rostami-Yazdi M, Clement B, Mrowietz U,. Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Arch Dermatol Res 2010; 302: 531-538.
10. Litjens NH, Nibbering PH, Barrois AJ, et al. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol 2003; 148: 444-451. (Pubitemid 36461322)
11. de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH,. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996; 26; 2067-2074. (Pubitemid 26297503)
12. Zhu K, Mrowietz U,. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol 2001; 116: 203-208. (Pubitemid 32173722)
13. Litjens NH, Rademaker M, Ravensbergen B, Thio HB, van Dissel JT, Nibbering PH,. Effects of monomethylfumarate on dendritic cell differentiation. Br J Dermatol 2006; 154: 211-217. (Pubitemid 43382688)
14. Treumer F, Zhu K, Glaser R, Mrowietz U,. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003; 121: 1383-1388. (Pubitemid 38005490)
15. Lehmann JC, Listopad JJ, Rentzsch CU, et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol 2007; 127: 835-845. (Pubitemid 46434667)
16. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M,. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998; 139: 390-395. (Pubitemid 28430453)
17. Rubant SA, Ludwig RJ, Diehl S, et al. Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression. J Invest Dermatol 2008; 128: 326-331.
18. Eberlein-Konig B, Mempel M, Stahlecker J, Forer I, Ring J, Abeck D,. Disseminated granuloma annulare-treatment with fumaric acid esters. Dermatology 2005; 210: 223-226. (Pubitemid 40529238)
19. Weber HO, Borelli C, Rocken M, Schaller M,. Treatment of disseminated granuloma annulare with low-dose fumaric acid. Acta Derm Venereol 2009; 89: 295-298.
20. Klein A, Landthaler M, Karrer S,. Pityriasis rubra pilaris: a review of diagnosis and treatment. Am J Clin Dermatol 2010; 11: 157-170.
21. Loewe R, Holnthoner W, Groger M, et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 2002; 168: 4781-4787. (Pubitemid 34441387)
22. Dutz JP,. T-cell-mediated injury to keratinocytes: insights from animal models of the lichenoid tissue reaction. J Invest Dermatol 2009; 129: 309-314.
23. Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN,. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003; 149: 363-369. (Pubitemid 37100263)
24. Häring N, Mähr HS, Mündle M, Strohal R, Lhotta K,. Early detection of renal damage caused by fumaric acid ester therapy by determination of urinary beta2-microglobulin. Br J Dermatol 2011; 164: 648-651.
25. Guenther CH, Wozel G, Laske J, Aschoff R, Meurer M,. Macular exanthema due to fumaric acid esters. Ann Pharmacother 2003; 37: 234-236. (Pubitemid 36172866)
26. Barth D, Simon JC, Wetzig T,. Malignant melanoma during treatment with fumaric acid esters-coincidence or treatment-related? J Dtsch Dermatol Ges 2011; 9: 223-225.
27. Hoxtermann S, Nuchel C, Altmeyer P,. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Dermatology 1998; 196: 223-230. (Pubitemid 28139451)
28. Jennings L, Murphy G,. Squamous cell carcinoma as a complication of fumaric acid ester immunosuppression. J Eur Acad Dermatol Venereol 2009; 23: 1451.
29. Wollina U,. Granuloma annulare disseminatum responding to fumaric acid esters. Dermatol Online J 2008; 14: 12.
30. Gutzmer R, Kapp A, Werfel T,. [Successful treatment of skin and lung sarcoidosis with fumaric acid ester]. Hautarzt 2004; 55: 553-557. (Pubitemid 38807992)
31. Gambichler T, Kreuter A, Freitag M, Pawlak FM, Brockmeyer NH, Altmeyer P,. Clearance of necrobiosis lipoidica with fumaric acid esters. Dermatology 2003; 207: 422-424. (Pubitemid 37505801)
32. Gutzmer R, Breuer K, Kiehl P, Kapp A, Werfel T,. Successful therapy of annular elastolytic giant cell granuloma with fumaric acid esters. Dermatology 2002; 205: 421-424. (Pubitemid 35356779)
33. Kreuter A, Gambichler T, Altmeyer P, Brockmeyer NH,. Treatment of disseminated granuloma annulare with fumaric acid esters. BMC Dermatol 2002; 2: 5.
34. Schulze-Dirks A, Petzoldt D,. [Granuloma annulare disseminatum: successful therapy with fumaric acid ester]. Hautarzt 2001; 52: 228-230. (Pubitemid 32217338)
35. Dümmler U, Rinke M, Sabel R, Gollnick H,. Sarkoidose mit kutaner Dissemination: Zwei Fälle unter Fumarsäuretherapie. [German]. Allergologie 1998; 8; 387. [Abstract]